Maxim Group analyst Naz Rahman has maintained their neutral stance on VRTX stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Hold rating due to a combination of factors impacting Vertex Pharmaceuticals. Despite the company’s strong financial performance in the second quarter of 2025, with revenues and earnings surpassing expectations, there are concerns about the long-term growth prospects. The launch of Alyftrek, a new cystic fibrosis therapy, is expected to cannibalize sales of Trikafta, and while it may eventually be beneficial due to lower royalty costs, it is not anticipated to significantly boost revenue or earnings per share.
Additionally, the demand for Journavx, a new pain therapy, is not expected to reach blockbuster levels due to its slow onset of action, and Casgevy’s sales growth is also uncertain. Furthermore, setbacks in the pain pipeline, including regulatory challenges and trial results, have limited Vertex’s market opportunities in this area. Given these factors, along with the company’s high valuation compared to its peers, Rahman maintains a Hold rating on Vertex’s stock.
In another report released today, Canaccord Genuity also maintained a Hold rating on the stock with a $411.00 price target.